Godshalk Welsh Capital Management Inc. lowered its holdings in Pfizer Inc. (NYSE:PFE) by 5.0% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 28,731 shares of the biopharmaceutical company’s stock after selling 1,500 shares during the quarter. Godshalk Welsh Capital Management Inc.’s holdings in Pfizer were worth $1,026,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Johnson Financial Group Inc. lifted its position in shares of Pfizer by 4.4% in the 3rd quarter. Johnson Financial Group Inc. now owns 134,527 shares of the biopharmaceutical company’s stock worth $4,802,000 after acquiring an additional 5,685 shares during the period. LVW Advisors LLC lifted its position in shares of Pfizer by 23.8% in the 3rd quarter. LVW Advisors LLC now owns 94,100 shares of the biopharmaceutical company’s stock worth $3,359,000 after acquiring an additional 18,111 shares during the period. Cadence Capital Management LLC lifted its position in shares of Pfizer by 5.2% in the 3rd quarter. Cadence Capital Management LLC now owns 375,768 shares of the biopharmaceutical company’s stock worth $13,415,000 after acquiring an additional 18,707 shares during the period. Hartland & Co. LLC lifted its position in shares of Pfizer by 13.6% in the 3rd quarter. Hartland & Co. LLC now owns 128,655 shares of the biopharmaceutical company’s stock worth $4,593,000 after acquiring an additional 15,451 shares during the period. Finally, Evergreen Capital Management LLC lifted its position in shares of Pfizer by 2.1% in the 3rd quarter. Evergreen Capital Management LLC now owns 91,961 shares of the biopharmaceutical company’s stock worth $3,283,000 after acquiring an additional 1,870 shares during the period. 70.06% of the stock is currently owned by hedge funds and other institutional investors.
Pfizer Inc. (NYSE PFE) opened at $34.94 on Wednesday. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $208,270.00, a P/E ratio of 9.93, a P/E/G ratio of 1.93 and a beta of 0.94. Pfizer Inc. has a 52-week low of $31.67 and a 52-week high of $39.43.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.06. The business had revenue of $13.70 billion during the quarter, compared to the consensus estimate of $13.67 billion. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. Pfizer’s revenue was up .6% on a year-over-year basis. During the same quarter last year, the company earned $0.47 EPS. analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer declared that its Board of Directors has initiated a stock buyback plan on Monday, December 18th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be given a $0.34 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date is Thursday, February 1st. This represents a $1.36 annualized dividend and a yield of 3.89%. Pfizer’s payout ratio is presently 38.64%.
In other Pfizer news, EVP Rady A. Johnson sold 8,000 shares of Pfizer stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the transaction, the executive vice president now owns 46,963 shares in the company, valued at approximately $1,740,918.41. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 6,750 shares of Pfizer stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the transaction, the insider now owns 103,458 shares of the company’s stock, valued at approximately $3,827,946. The disclosure for this sale can be found here. Insiders own 0.06% of the company’s stock.
A number of analysts have commented on PFE shares. SunTrust Banks reiterated a “hold” rating and issued a $40.00 price objective (up previously from $33.00) on shares of Pfizer in a research report on Monday, January 29th. BMO Capital Markets reiterated a “buy” rating and issued a $39.00 price objective on shares of Pfizer in a research report on Friday, November 10th. Jefferies Group set a $39.00 price objective on Pfizer and gave the stock a “neutral” rating in a research report on Thursday, October 26th. Vetr upgraded Pfizer from a “hold” rating to a “buy” rating and set a $37.98 price objective for the company in a research report on Monday, January 8th. Finally, Berenberg Bank set a $36.00 price objective on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, October 31st. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $39.45.
ILLEGAL ACTIVITY WARNING: “Pfizer Inc. (PFE) Shares Sold by Godshalk Welsh Capital Management Inc.” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/02/14/pfizer-inc-pfe-shares-sold-by-godshalk-welsh-capital-management-inc.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.